FDA Inspection
Resilience US, Inc.Resilience US, Inc. – FDA Inspection, Aug 11, 2017
Record Details
This FDA Inspection record concerns Resilience US, Inc., with an inspection on August 11, 2017, issued by the Center for Drug Evaluation and Research, covering drugs.
- People
- Diane L. Raccasi (Issuing Officer)
- Edmund F. Mrak (FDA Associated Person)
View Company Profile
ID · 7149db55-a0d6-45a9-b927-d89a977a24d4
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1021959
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
- Outcome
- Form 483 issued
Other FDA inspections of Resilience US, Inc.
6| Date | Classification | Office | Project area |
|---|---|---|---|
| August 21, 2019 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| September 14, 2017 | NAI | Center for Drug Evaluation and Research | Bioresearch Monitoring |
| September 25, 2014 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| November 13, 2009 | OAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| May 28, 2009 | OAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Resilience US, Inc.
- FDA Inspection 1102300 - 2019-08-21
- FDA Inspection 1028333 - 2017-09-14
- FDA Inspection 897817 - 2014-09-25
- FDA Inspection 625796 - 2009-11-13
- FDA Inspection 595314 - 2009-05-28
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.